| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating expenses: | $53.4M+39183.1% | $136K-86.8% | $1.0M | $0 | $0 |
| Cost of Revenue | $29.3M+43673.1% | $67K-66.5% | $200K | $0 | $0 |
| Research and development | $581.1M+21.8% | $477.2M+30.0% | $367.0M+23.9% | $296.3M+50.0% | $197.6M |
| Selling, general and administrative | $162.6M+35.9% | $119.7M+13.0% | $105.9M+10.4% | $95.9M+55.9% | $61.5M |
| Total operating expenses | $773.0M+29.5% | $596.9M+26.2% | $473.1M+20.6% | $392.2M+51.4% | $259.1M |
| Loss from operations | -$719.6M-20.6% | -$596.8M-26.4% | -$472.1M-20.4% | -$392.2M-51.4% | -$259.1M |
| Interest and other income, net | $43.2M+0.8% | $42.8M-6.0% | $45.6M+171.4% | $16.8M | — |
| Loss on common stock issuance in private placement | -$40.3M | $0 | $0 | — | — |
| Loss from change in fair value of warrants, earnout shares and contingent consideration | -$211.8M-292.5% | -$54.0M+37.5% | -$86.4M | — | — |
| Total other loss, net | -$208.9M-1773.8% | -$11.2M+72.7% | -$40.8M-130.4% | $134.3M+96.8% | $68.2M |
| Loss before income taxes | -$928.5M-52.7% | -$607.9M-18.5% | -$512.9M-98.8% | -$258.0M-35.2% | -$190.9M |
| Income tax expense | $1.3M+913.2% | $129K-7.2% | $139K+51.1% | $92K+100.9% | -$10.5M |
| Net loss | -$929.8M-52.9% | -$608.0M-18.5% | -$513.0M-98.8% | -$258.0M-43.1% | -$180.3M |
| Net loss per share, basic (in dollars per share) | -$1130.00-29.9% | -$870.00-10.1% | -$790.00-79.5% | -$440.00+27.9% | -$610.00 |
| Net loss per share, diluted (in dollars per share) | -$1130.00-29.9% | -$870.00-10.1% | -$790.00-79.5% | -$440.00+27.9% | -$610.00 |
| Weighted-average common shares outstanding, basic (in shares) | 826.24B+18.1% | 699.79B+8.0% | 647.91B+10.7% | 585.54B+98.6% | 294.85B |
| Weighted-average common shares outstanding, diluted (in shares) | 826.24B+18.1% | 699.79B+8.0% | 647.91B+10.7% | 585.54B+98.6% | 294.85B |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Source: SEC EDGAR 10-K and 10-Q filings. Up to 10 years annual / 16 quarters shown.